Fluticasone propionate clinical studies
Pro Research Analysisby 
Searched over 200M research papers
Fluticasone Propionate Clinical Studies: Efficacy, Safety, and Applications
Fluticasone Propionate in Asthma: Dose-Response and Comparative Efficacy
Multiple clinical studies have shown that fluticasone propionate (FP) is a potent inhaled corticosteroid for asthma management, offering significant improvements in lung function, symptom control, and reduction in exacerbations. Dose-ranging studies in adults with moderate asthma demonstrated a clear dose-related improvement in lung function, peak expiratory flow rates, and symptom-free days, with higher doses leading to greater benefits and reduced need for rescue bronchodilators. Importantly, these improvements were achieved without significant systemic side effects or hypothalamic-pituitary-adrenal axis suppression, and FP was generally well tolerated across all dose groups Dahl1993Nathan2000Wolfe1996.
Comparative studies have found that FP is at least as effective, if not more so, than other inhaled corticosteroids such as beclomethasone dipropionate and budesonide, often at half the dosage. FP provided greater improvements in peak expiratory flow and asthma control, with fewer severe exacerbations and no increase in systemic side effects, even at high doses over long-term use Fuller1995Holliday1994Fabbri1993. These findings support FP as a preferred option for both moderate and severe asthma, including in children, with a favorable safety profile Fuller1995Holliday1994.
Fluticasone Propionate in Chronic Obstructive Pulmonary Disease (COPD)
Clinical trials in patients with moderate to severe COPD have shown that inhaled FP can reduce the frequency and severity of exacerbations, improve lung function, and slow the decline in health status. While FP did not significantly affect the annual rate of decline in FEV1, it did produce a small but sustained increase in FEV1, reduced median exacerbation rates, and led to fewer respiratory-related withdrawals compared to placebo. Health status also deteriorated more slowly in patients treated with FP Paggiaro1998Burge2000. FP was well tolerated, with few adverse effects and no clinically important impact on serum cortisol concentrations Paggiaro1998Burge2000.
Fluticasone Propionate in Eosinophilic Esophagitis and Osteoarthritis
Beyond respiratory diseases, FP has been studied in other conditions. In eosinophilic esophagitis, an orally disintegrating tablet formulation (APT-1011) showed high rates of histologic response, significant improvements in endoscopic features, and reduced dysphagia frequency compared to placebo. The treatment was generally safe, with candidiasis being the main side effect at higher doses .
A novel extended-release intra-articular injection of FP (EP-104IAR) for knee osteoarthritis provided clinically meaningful pain relief for up to 14 weeks, longer than currently available corticosteroids. The treatment was well tolerated, with minimal effects on glucose and cortisol, and no serious adverse events .
Pharmacological Properties and Safety Profile
FP is highly lipophilic, with strong glucocorticoid receptor selectivity and affinity, leading to potent anti-inflammatory effects in the lungs and nasal mucosa. It is minimally absorbed from the gastrointestinal tract, resulting in low systemic bioavailability and a potentially improved safety profile compared to other corticosteroids. Long-term studies have not shown significant pituitary-adrenal suppression or effects on growth in children, though further research is needed to confirm these findings over extended periods Fuller1995Holliday1994.
Conclusion
Clinical studies consistently demonstrate that fluticasone propionate is a highly effective and well-tolerated corticosteroid for asthma and COPD, with additional benefits in eosinophilic esophagitis and osteoarthritis. Its favorable safety profile, potent anti-inflammatory action, and efficacy at lower doses compared to other corticosteroids make it a valuable option in the management of these chronic conditions Fuller1995Dahl1993Nathan2000+7 MORE.
Sources and full results
Most relevant research papers on this topic
Fluticasone propionate--an update on preclinical and clinical experience.
Fluticasone propionate has twice the clinical potency of beclomethasone dipropionate and budesonide for treating rhinitis and asthma, with a higher therapeutic index compared to other available inhaled corticosteroids.
A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma.
Once-daily fluticasone propionate treatment is well-tolerated and shows dose-related trends in improvements in lung function and asthma control in patients with moderate asthma.
Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group.
Inhaled fluticasone propionate may improve lung function and reduce symptoms in COPD patients, with few adverse effects and no significant effect on serum cortisol concentration.
Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma.
Inhaled fluticasone propionate offers an effective treatment option for asthma management with potential enhanced safety, offering a low oral bioavailability and potentially enhanced tolerability profile.
Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial.
APT-1011 is a safe and effective oral treatment for eosinophilic esophagitis, with 3 mg once daily at bedtime showing the most favorable risk-benefit profile.
DOI